Indirect protection obtained by Haemophilus influenzae type b vaccination: analysis in a structured population model

We used a structured population model to study factors determining the magnitude of indirect protection in Haemophilus influenzae type b (Hib) vaccination. On a simulation platform mimicking the population of Finland, a Hib transmission and immunity model, including cross-reactive bacterial encounters, was formulated. Utilizing different vaccination coverages and vaccine types we could study how fast the incidence of Hib disease declined due to direct and indirect vaccination effects. With the Finnish vaccination schedule we could reproduce the observed disappearance of Hib cases. Our results show that an indirect effect was already significant with a relatively low vaccine coverage, even with a vaccine only partly reducing carriage acquisition. This suggests that the vaccination schedule and vaccine to be used should be chosen to result, in addition to immunological memory, in high antibody concentrations, sufficient to reduce carriage, the latter being the main factor behind successful elimination of transmission and disease.

[1]  K. Auranen,et al.  Modelling transmission, immunity and disease of Haemophilus influenzae type b in a structured population , 2004, Epidemiology and Infection.

[2]  K. Auranen,et al.  Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. , 2003, Vaccine.

[3]  M. Ramsay,et al.  Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. , 2003, Communicable disease and public health.

[4]  M. Steinhoff,et al.  Conjugate Hib vaccines , 2003, The Lancet.

[5]  K. Auranen,et al.  Haemophilus influenzae type b and cross-reactive antigens in natural Hib infection dynamics; modelling in two populations , 2002, Epidemiology and Infection.

[6]  Elja Arjas,et al.  Transmission of Pneumococcal Carriage in Families: A Latent Markov Process Model for Binary Longitudinal Data , 2000 .

[7]  J. Deeks,et al.  Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. , 2000, JAMA.

[8]  S. Romero-Steiner,et al.  Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. , 2000, The Journal of infectious diseases.

[9]  R. Singleton,et al.  Experience with the prevention of invasive Haemophilus influenzae type b disease by vaccination in Alaska: the impact of persistent oropharyngeal carriage. , 2000, The Journal of pediatrics.

[10]  M. Santosham.  Can Haemophilus influenzae type b disease be eliminated from the United States? , 2000, The Journal of pediatrics.

[11]  G. Garnett,et al.  The Hib immunization programme in the Oxford region: an analysis of the impact of vaccine administration on the incidence of disease , 1999, Epidemiology and Infection.

[12]  G. Garnett,et al.  Mathematical models of Haemophilus influenzae type b , 1998, Epidemiology and Infection.

[13]  S. Jaffar,et al.  Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. , 1998, The Journal of infectious diseases.

[14]  Rosanna Lagos,et al.  Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens , 1998, The Lancet.

[15]  A. van der Ende,et al.  Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity. , 1997, The Journal of pediatrics.

[16]  D. Crook,et al.  Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T , 1997, Archives of disease in childhood.

[17]  E. Moxon,et al.  Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster , 1997, The Lancet.

[18]  M. Barbour,et al.  Conjugate vaccines and the carriage of Haemophilus influenzae type b. , 1996, Emerging infectious diseases.

[19]  P. Mäkelä,et al.  Comparison of five different vaccination schedules with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. , 1996, The Journal of pediatrics.

[20]  J. van Marle,et al.  Antibodies to Haemophilus influenzae type b polysaccharide affect bacterial adherence and multiplication , 1996, Infection and immunity.

[21]  J. Eskola,et al.  Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. , 1995, The Pediatric infectious disease journal.

[22]  D. Crook,et al.  The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. , 1995, The Journal of infectious diseases.

[23]  P. Mäkelä,et al.  Clinical comparison of the Haemophilus influenzae type B polysaccharide-diphtheria toxoid and the oligosaccharide-CRM197 protein vaccines in infancy. , 1994, Archives of pediatrics & adolescent medicine.

[24]  G. W. Letson,et al.  Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants , 1993, The Pediatric infectious disease journal.

[25]  H. Chapel,et al.  Antibody persistence after accelerated immunisation against Haemophilus influenzae type b. , 1993, BMJ.

[26]  R. Belshe,et al.  Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. , 1992, The Journal of pediatrics.

[27]  K. Edwards,et al.  Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. , 1992, The Journal of pediatrics.

[28]  M. Leinonen,et al.  Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. , 1991, The Journal of infectious diseases.

[29]  P. Mäkelä,et al.  A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. , 1990, The New England journal of medicine.

[30]  H. Valkenburg,et al.  Carriage of Haemophilus influenzae in healthy Gambian children. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[31]  Denis Mollison,et al.  The Analysis of Infectious Disease Data. , 1989 .

[32]  P. Mäkelä,et al.  Epidemiology of invasive Haemophilus influenzae type b disease among children in Finland before vaccination with Haemophilus influenzae type b conjugate vaccine. , 1989, The Pediatric infectious disease journal.

[33]  E. Moxon,et al.  Meningitis caused by Haemophilus influenzae in infant rats: protective immunity and antibody priming by gastrointestinal colonization with Escherichia coli. , 1979, The Journal of infectious diseases.

[34]  C. Norden,et al.  Pharyngeal colonization with Haemophilus influenzae type b: a longitudinal study of families with a child with meningitis or epiglottitis due to H. influenzae type b. , 1977, The Journal of infectious diseases.

[35]  J. C. Parke,et al.  Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b. , 1971, Lancet.